Barclays raised the firm’s price target on National Vision (EYE) to $30 from $28 and keeps an Overweight rating on the shares following the investor day. The company reiterated fiscal 2025 guidance and provided long-term targets, the analyst tells investors in a research note. The firm remains “strongly positive” on National Vision’s transformative efforts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYE:
- Strategic Growth and Market Expansion Drive Buy Rating for National Vision Holdings
- National Vision Holdings: Strategic Growth Initiatives and Expansion Plans Drive Buy Rating
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- National Vision announces transformation strategy
- National Vision sees FY26 revenue growth in high-single digits